The development of biomarkers based on quantitative imaging provides powerful non-invasive and cost effective diagnostic tools for stratified medicine. Capitalising on their multidisciplinary team of experts, Brainomix Limited, a start-up company from the University of Oxford, aims to become a leader in imaging biomarkers for neurological and cerebrovascular disorders.
From our roots in the University's software incubator, our vision is to equip physicians with automated medical imaging tools that will allow them to select the right patient for the right treatment.
The company's flagship product is the e-ASPECTS software. This automatically implements the Alberta Stroke Program Early CT Score (ASPECTS) clinical scoring methodology for detecting and assessing signs of stroke damage on computed tomography (CT) scans from patients with acute stroke. ASPECTS was invented by Professor Alastair Buchan, a co-founder of Brainomix and the Dean of Medicine and Professor of Stroke Medicine at the University of Oxford. The software will assist clinicians worldwide with the assessment of patient eligibility for life saving treatment. It will be used both by hospitals offering a stroke service and stroke clinical trials, providing major benefits to patients and the healthcare system.
The Brainomix co-founders and team consist of clinicians, scientists, technologists and business professionals specializing in neurology, neuroscience and medical imaging fields. Brainomix is ideally positioned to commercialise innovative medical imaging technologies that will revolutionise and improve the treatment of patients with neurological and cerebrovascular disorders.
Location: United Kingdom, England, Oxford
Phone: +44 1865 582730
Total raised: $31.32M
Investors 1
Date | Name | Website |
- | Parkwalk A... | parkwalkad... |
Funding Rounds 2
Date | Series | Amount | Investors |
23.12.2021 | Series B | $21.47M | - |
03.04.2018 | - | $9.85M | - |
Mentions in press and media 27
Date | Title | Description | Source |
22.03.2023 | Brainomix Receives FDA Clearance for Its Flagship Stroke AI ... | Brainomix, the AI-powered medtech solutions company, announced that its Brainomix 360 e-ASPECTS tool... | aithority.... |
01.03.2023 | Parkwalk – Meet the Portfolio series | As part of our annual Portfolio Showcase in 2022, we had the opportunity to sit down with some of ou... | parkwalkad... |
08.01.2023 | Глубокое обучение в диагностике: как AI спасает жизни и экон... | Разница между современными моделями ML и XAI. Источник: DARPA Разрабатываемые сейчас решения XAI пр... | vc.ru/ml/5... |
06.12.2022 | Глубокое обучение в диагностике: как AI спасает жизни и экон... | «Симптомы никогда не лгут», — так сказал самый блестящий диагност, доктор Хаус, который, увы существ... | habr.com/r... |
25.11.2022 | Brainomix announces new partnership with Pixyl to expand its... | Brainomix to distribute Pixyl.Neuro.MS Software as a Service (SaaS) solution exclusively in the UK a... | einpresswi... |
23.12.2021 | Brainomix secures £16M to expand AI-based platform for bioma... | Credit: Brainomix The British medtech company Brainomix has announced that it has closed a series B... | mobihealth... |
22.12.2021 | Greek-founded Brainomix raised over €18M to scale its AI sol... | Athens, Greece ~ Company: British MedTech startup Brainomix, which has a Greek co-founder, raised ... | therecursi... |
17.12.2021 | UK medtech startup Brainomix raises £16M | Oxford-based medtech startup Brainomix has closed a £16 million Series B co-led by existing investor... | pitchbook.... |
16.12.2021 | Brainomix Closes £16M ($21.2M) Financing Round to Expand Its... | OXFORD, United Kingdom, Dec. 16, 2021 /PRNewswire/ -- Brainomix, the AI-powered medtech solutions co... | marketscre... |
16.12.2021 | Brainomix Closes £16M ($21.2M) Financing Round To Expand Its... | The Series B investment will enable the Oxford-based company to expand its award-winning artificial ... | aithority.... |
Show more